About
Home retinal monitoring-as-a-service: patients self-run OCT in their own homes with AI tracking biomarkers, sold with a monitoring service centre. Targets the AMD/anti-VEGF population between injections.
HQ: Manassas, VA, USA (R&D Tel Aviv)
Funding
Up to $60M round (2021); ~$110M total per PitchBook
Trackers range $85–$110M.